Enducal, Nida P.
HRN: 15-51-18 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/25/2022
CEFTRIAXONE 1G (VIAL)
05/25/2022
06/01/2022
IV
2g
Od
Cap-mr
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes